Skip to main content
Premium Trial:

Request an Annual Quote

BioMark Diagnostics, Rubix LS Partner for Liquid Biopsy Cancer Screening in Underserved Communities

NEW YORK – BioMark Diagnostics and medical research organization Rubix LS said Wednesday that they have initiated a strategic partnership aimed at developing better lung cancer and breast cancer liquid biopsy screening tests, with a focus on reaching underserved communities.

Financial terms of the deal were not disclosed.

The companies said the initiative will harness Rubix LS's strength as a "culturally competent research catalyst," with CLIA-certified and CAP-accredited clinical laboratory capacity to perform screening and conduct necessary clinical studies using BioMark's blood-based test technology.

Vancouver, Canada-based BioMark has been developing a liquid biopsy platform based on metabolomics and machine learning algorithms for early cancer detection, treatment response monitoring, and potentially for serial recurrence monitoring of cancer survivors.

Previous partnerships include a collaboration with the Icahn School of Medicine at Mount Sinai in New York to develop early-stage lung cancer diagnostics and with pharma firms AstraZeneca and Pfizer Canada.